Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

Abstract Objective To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients w...

Full description

Bibliographic Details
Main Authors:	Yan Gao, Yuan Li, Chunyu Zhang, Jinsong Han, Huamao Liang, Kun Zhang, Hongyan Guo
Format:	Article
Language:	English
Published:	BMC 2019-09-01
Series:	Journal of Ovarian Research
Subjects:	Advanced ovarian epithelial Cancer Neoadjuvant chemotherapy Primary Debulking surgery Chemoresistance Prognosis
Online Access:	http://link.springer.com/article/10.1186/s13048-019-0562-9

Similar Items

AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
by: Wang Y, et al.
Published: (2016-04-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
by: Lu Qin, et al.
Published: (2018-06-01)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
by: Minjun He, et al.
Published: (2021-03-01)

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
by: Kobal Borut, et al.
Published: (2018-09-01)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
by: Kazuto Nakamura, et al.
Published: (2020-08-01)

A comparison between primary debulking surgery and primary chemotherapy in patients with advanced ovarian cancer: a retrospective study
by: Mohamed Esmat, et al.
Published: (2018-01-01)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
by: Škof Erik, et al.
Published: (2016-09-01)

Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer
by: LIU Chuanzhong, et al.
Published: (2018-10-01)

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
by: Xiaoli He, et al.
Published: (2021-06-01)

Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort
by: Zheng Feng, et al.
Published: (2021-02-01)

Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute
by: Monisha Gupta, et al.
Published: (2020-01-01)

Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer
by: Merlo Sebastjan, et al.
Published: (2021-08-01)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer
by: Forde GK, et al.
Published: (2016-08-01)

Cisplatin, cyclophosphamide versus taxol, carboplatin in epithelial ovarian carcinoma: a clinical trial
by: Modarres M, et al.
Published: (2007-05-01)

The role of cytoreduction surgery in advanced ovarian cancer (review)
by: R K Tandelov, et al.
Published: (2018-03-01)

Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
by: Ami Patel, et al.
Published: (2021-02-01)

Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer
by: Emre Günakan, et al.
Published: (2020-01-01)

A Prediction Model for Optimal Primary Debulking Surgery Based on Preoperative Computed Tomography Scans and Clinical Factors in Patients With Advanced Ovarian Cancer: A Multicenter Retrospective Cohort Study
by: Yu Gu, et al.
Published: (2021-01-01)

Morphology: A Keystone in Therapeutic Decision Making of Post Therapy Tumour Regression in Ovarian Tumours
by: K CHANDRAMOULEESWARI, et al.
Published: (2018-11-01)

Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research
by: Edward Wenge Wang, et al.
Published: (2020-09-01)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
by: Yong Jae Lee, et al.
Published: (2020-03-01)

Neoadjuvant chemotherapy for IIIC stage ovarian cancer - case report
by: Aleksandra Obuchowska, et al.
Published: (2020-09-01)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
by: Huaqin Lin, et al.
Published: (2021-05-01)

Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial
by: Soo Jin Park, et al.
Published: (2020-05-01)

Gut Microbiota Dynamics during Chemotherapy in Epithelial Ovarian Cancer Patients Are Related to Therapeutic Outcome
by: Federica D’Amico, et al.
Published: (2021-08-01)

Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer
by: Abhilash Deo, et al.
Published: (2020-01-01)

Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells
by: Bin Shang, et al.
Published: (2017-04-01)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
by: Xiaotang Yu, et al.
Published: (2020-11-01)

Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynx
by: Poonam Joshi, et al.
Published: (2017-01-01)

Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram
by: Wei-feng Liang, et al.
Published: (2020-10-01)

Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN)
by: Virginie Bund, et al.
Published: (2020-07-01)

Prognostic Significance of Log(CA125)/PCI for the Resectability of Epithelial Ovarian Cancer: A Retrospective Study
by: He C, et al.
Published: (2020-03-01)

A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy
by: Kyung Jin Eoh, et al.
Published: (2017-07-01)

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
by: Dengfeng Wang, et al.
Published: (2021-03-01)

Neoadjuvant chemotherapy for advanced ovarian cancer: literature data and in vitro studies
by: S. A. Kuznetsov, et al.
Published: (2015-09-01)

Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience
by: Gao T, et al.
Published: (2019-07-01)

Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402)
by: Tomoko Hirakawa, et al.
Published: (2017-07-01)

Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery
by: Christopher G. Smith, et al.
Published: (2019-07-01)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
by: Jorge A. Alegría-Baños, et al.
Published: (2021-07-01)